EE187 Umeclidinium/Vilanterol Versus Tiotropium/Olodaterol in the Treatment of Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD) from the Brazilian Public Healthcare System Perspective: A Budget Impact Analysis

Abstract

Umeclidinium/vilanterol (UMEC/VIL) and tiotropium/olodaterol (TIO/OLO), both combinations of long-acting muscarinic antagonist and long-acting beta2-adrenergic (LAMA/LABA) with similar efficacy and safety, are reimbursed for COPD treatment in Brazilian Public Healthcare System (SUS) since 2020. In 2021/2022, according to the Brazilian Government Price Panel (PP), TIO/OLO public sales volume were four times higher compared to UMEC/VIL. Our aim was to estimate the budget impact analysis (BIA) of switching TIO/OLO to UMEC/VIL for severe to very severe COPD treatment in SUS.